Peptide blends

The canonical healing pair. BPC-157 drives angiogenesis and gut/tendon repair; TB-500 drives cell migration and tissue migration. The mechanisms are complementary, and most chronic-injury protocols pair them for a stronger combined effect than either alone.

Chronic soft-tissue injuries that haven't resolved on their own. Lifters with stubborn tendon or ligament pain. Post-surgical recovery contexts under medical guidance.

Running them as a blend is convenient, one injection, one vial. Running them separately gives you the freedom to titrate each independently and to load TB-500 (twice weekly) on a different schedule than BPC (daily). For users new to peptides, the blend is simpler. For users dialing in protocols, singles give more control.

Community nickname for an aggressive recovery + connective-tissue stack. BPC-157 + TB-500 is the canonical healing pair (angiogenesis + cell migration). GHK-Cu adds collagen synthesis and skin-layer support. Named after the comic-book character for the 'heals everything' marketing angle. Not a clinical protocol, a vendor and community label.

Chronic soft-tissue injuries plus skin / scar tissue concerns. Lifters or athletes wanting both internal repair and external skin support in one stack.

Same trade-off as any 3-compound blend: easier to handle as one vial, but you lose the ability to dial in GHK-Cu independently (which has different storage and dose requirements). Singles win when you want to taper or rotate components.

The standard GH-axis stack. CJC-1295 (no-DAC version) is a GHRH analog, it tells the pituitary 'release GH'. Ipamorelin is a GH-secretagogue, it amplifies the same pulse via a different receptor. Together they produce a stronger natural GH release than either alone, while preserving the body's pulse rhythm. The 'no-DAC' version is specifically chosen so the half-life stays short and the pulses stay distinct.

Recovery, sleep, and slow body-comp shifts without the side effect baggage of injecting actual HGH. Beginners to GH-axis work who want the gentlest entry point.

Running them as a blend is the norm, they're almost always paired. Running them separately is rare and adds no benefit because they're meant to fire together. Pre-bed dose is the priority pulse.

Skin and connective-tissue stack. GHK-Cu drives collagen synthesis and supports follicle activity. BPC-157 + TB-500 add the systemic healing layer underneath. Common label name in vendor blends; not a clinical protocol, a community-named combination.

Users running aggressive skin / anti-aging routines who also want healing-stack benefits. Post-microneedling or post-procedure recovery contexts.

GHK-Cu has its own dose math (1-2 mg sub-q daily) and uses glass storage because copper binds plastic. Pre-blended GLOW vials simplify the practical handling but don't let you adjust GHK-Cu independently. Singles win if you want to dial in GHK-Cu at a different rate than the BPC/TB pair. Often paired with non-peptide adjuncts: glutathione (IV or oral) for the antioxidant + skin-brightening layer.

GLOW with KPV added for the anti-inflammatory layer. KPV (a tripeptide fragment of alpha-MSH) is the canonical anti-inflammatory peptide and pairs naturally with BPC-157 for gut protocols. KLOW is the most aggressive 'fix everything connective and inflammatory' blend in the community vocabulary.

Users with chronic inflammatory components alongside connective-tissue issues. Gut + skin + tendon overlap cases. Most aggressive of the healing-family blends.

Same trade-off as GLOW. Blend simplifies handling; singles give per-component control. KPV in particular benefits from independent titration in users with mast-cell sensitivity.

Different appetite-control pathways combined. Semaglutide is a GLP-1 agonist (gut-derived satiety signal). Cagrilintide is an amylin agonist (pancreas-derived satiety signal). Phase 3 data continues to support the combination breaking past Semaglutide-monotherapy plateaus. Novo Nordisk is developing it as a single-drug product.

Users who plateaued on Semaglutide alone. People wanting GLP-tier weight loss with a slightly cleaner side effect profile than higher-dose monotherapy.

If you're already on Semaglutide and stalled, adding Cagrilintide is the move (singles approach). If you're starting fresh and want the combination effect, the pre-blended product is simpler. Often paired with non-peptide adjuncts: L-Carnitine to preserve fatty-acid oxidation during the cut, berberine for the AMPK angle, methylene blue for mitochondrial support.

Two GH-axis levers in one stack. Tesamorelin is FDA-approved for HIV-associated lipodystrophy and specifically targets visceral fat. Ipamorelin amplifies the GH pulse with cleaner side effects than Hexarelin or GHRP-2. The combination is community-popular for users who want both the visceral-fat-targeting effect and the cleaner pulse on top.

Users with elevated visceral fat targeting body comp via the GH axis. Older adults running anti-aging protocols who want a stronger GH-axis lift than CJC+Ipa alone.

Tesamorelin works on its own and is FDA-approved on its own. Adding Ipamorelin is an off-label community pattern, not a clinical protocol. Singles give you the option to step Tesamorelin alone first and verify response before adding the secretagogue layer.

Calm + clear. Selank is on the anxiolytic end of the spectrum; Semax is on the alert/focus end. Both are Russian-origin nootropic peptides. Combining them theoretically gives you the calm baseline of Selank with the focus lift of Semax, useful in demanding work contexts.

Users with situational anxiety AND cognitive-load demands. People tapering off stimulants or benzos under medical guidance who want a gentler combination.

Both peptides have meaningful effects on their own. Most users start with one, learn what it feels like, then add the other if they want to round out the profile. Pre-blended is convenient but obscures which peptide is doing what for you.

Mitochondrial stack. SS-31 (Elamipretide) concentrates in the inner mitochondrial membrane and supports ATP production. MOTS-c is mitochondrial-derived and tied to insulin sensitivity. Combining them targets cellular bioenergetics from two complementary angles. Less clinical evidence than the GLP and healing classics, treat as experimental.

Older adults or hard-training athletes targeting cellular bioenergetics. Users with mitochondrial-flavored fatigue under medical guidance.

Limited data on either compound makes attribution hard when you stack them. If signal matters more to you than convenience, run singles and rotate.